IN2012DN00797A - - Google Patents
Download PDFInfo
- Publication number
- IN2012DN00797A IN2012DN00797A IN797DEN2012A IN2012DN00797A IN 2012DN00797 A IN2012DN00797 A IN 2012DN00797A IN 797DEN2012 A IN797DEN2012 A IN 797DEN2012A IN 2012DN00797 A IN2012DN00797 A IN 2012DN00797A
- Authority
- IN
- India
- Prior art keywords
- relates
- present
- monoclonal antibody
- antibody
- aureus
- Prior art date
Links
- 101710092462 Alpha-hemolysin Proteins 0.000 abstract 1
- 101710197219 Alpha-toxin Proteins 0.000 abstract 1
- 101710124951 Phospholipase C Proteins 0.000 abstract 1
- 206010000269 abscess Diseases 0.000 abstract 1
- 239000002776 alpha toxin Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Biotechnology (AREA)
- Radiology & Medical Imaging (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09010311A EP2284193A1 (en) | 2009-08-10 | 2009-08-10 | Human monoclonal antibody against S. aureus derived apha-toxin and its use in treating or preventing abscess formation |
| US26633009P | 2009-12-03 | 2009-12-03 | |
| PCT/EP2010/004884 WO2011018208A1 (en) | 2009-08-10 | 2010-08-10 | Human monoclonal antibody against s. aureus derived alpha-toxin and its use in treating or preventing abscess formation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2012DN00797A true IN2012DN00797A (enExample) | 2015-06-26 |
Family
ID=41381987
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN797DEN2012 IN2012DN00797A (enExample) | 2009-08-10 | 2010-08-10 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9249215B2 (enExample) |
| EP (3) | EP2284193A1 (enExample) |
| JP (1) | JP6064241B2 (enExample) |
| KR (1) | KR101836130B1 (enExample) |
| CN (1) | CN102549013B (enExample) |
| CA (1) | CA2769394C (enExample) |
| ES (2) | ES2529175T3 (enExample) |
| IL (1) | IL217746A (enExample) |
| IN (1) | IN2012DN00797A (enExample) |
| RU (1) | RU2529946C9 (enExample) |
| WO (1) | WO2011018208A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140286960A1 (en) * | 2011-07-28 | 2014-09-25 | Cangene Corporation | Staphlococcus aureus alpha-hemolysin antibodies |
| WO2013093693A1 (en) * | 2011-12-22 | 2013-06-27 | Rinat Neuroscience Corp. | Staphylococcus aureus specific antibodies and uses thereof |
| AU2013251165B2 (en) * | 2012-04-17 | 2017-08-24 | Arsanis Biosciences Gmbh | Cross-reactive Staphylococcus aureus antibody |
| JP6506172B2 (ja) | 2012-11-06 | 2019-04-24 | メディミューン，エルエルシー | 黄色ブドウ球菌（Ｓ．ａｕｒｅｕｓ）関連性疾患を治療する方法 |
| JP6694269B2 (ja) * | 2012-11-06 | 2020-05-13 | メディミューン，エルエルシー | Ｓ．アウレウス（Ｓ．ａｕｒｅｕｓ）表面決定基に対する抗体 |
| CN104211804A (zh) * | 2014-08-20 | 2014-12-17 | 钱泓 | 一种抗金黄色葡萄球菌多克隆抗体的制备与应用 |
| TW202311284A (zh) | 2017-01-03 | 2023-03-16 | 美商再生元醫藥公司 | 抗金黃色葡萄球菌溶血素ａ毒素之人類抗體 |
| US20220275088A1 (en) * | 2019-06-14 | 2022-09-01 | Dana-Farber Cancer Institute, Inc. | Antibodies against pd-1 and methods of use thereof |
| CN112538112B (zh) * | 2019-09-20 | 2023-10-27 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其应用 |
| CN113444172A (zh) | 2020-03-25 | 2021-09-28 | 兴盟生物医药(苏州)有限公司 | 金黄色葡萄球菌α-毒素特异性抗体及其应用 |
| WO2021212021A2 (en) * | 2020-04-16 | 2021-10-21 | Dana-Farber Cancer Institute, Inc. | Coronavirus antibodies and methods of use thereof |
| CN113698478B (zh) * | 2020-05-21 | 2025-11-18 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| WO2023208123A1 (zh) * | 2022-04-28 | 2023-11-02 | 珠海泰诺麦博制药股份有限公司 | 特异性结合金黄色葡萄球菌Hla毒素的全人源单克隆抗体 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69734601T2 (de) * | 1996-05-16 | 2006-08-03 | The Texas A & M University System, College Station | Zusammensetzung von kollagenbindungsprotein und verfahren zu deren verwendungen |
| CN103351435B (zh) * | 2006-06-06 | 2015-08-19 | 克鲁塞尔荷兰公司 | 具有杀灭葡萄球菌活性的人结合分子及其应用 |
| EP2719397A1 (en) | 2006-06-12 | 2014-04-16 | GlaxoSmithKline Biologicals SA | Use of alpha-toxin for treating and preventing staphylococcus infections |
| KR101661946B1 (ko) * | 2007-08-31 | 2016-10-05 | 유니버시티 오브 시카고 | 스타필로코커스 폐 질환 및 상태에 대한 면역화와 관련된 방법 및 조성물 |
-
2009
- 2009-08-10 EP EP09010311A patent/EP2284193A1/en not_active Withdrawn
-
2010
- 2010-08-10 WO PCT/EP2010/004884 patent/WO2011018208A1/en not_active Ceased
- 2010-08-10 US US13/388,254 patent/US9249215B2/en active Active
- 2010-08-10 CA CA2769394A patent/CA2769394C/en active Active
- 2010-08-10 KR KR1020127004737A patent/KR101836130B1/ko not_active Expired - Fee Related
- 2010-08-10 ES ES10743037.3T patent/ES2529175T3/es active Active
- 2010-08-10 JP JP2012524142A patent/JP6064241B2/ja not_active Expired - Fee Related
- 2010-08-10 RU RU2012105045/10A patent/RU2529946C9/ru active
- 2010-08-10 EP EP10743037.3A patent/EP2464665B1/en active Active
- 2010-08-10 EP EP14195810.8A patent/EP2860191B1/en active Active
- 2010-08-10 ES ES14195810.8T patent/ES2651762T3/es active Active
- 2010-08-10 CN CN201080044958.0A patent/CN102549013B/zh active Active
- 2010-08-10 IN IN797DEN2012 patent/IN2012DN00797A/en unknown
-
2012
- 2012-01-26 IL IL217746A patent/IL217746A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| IL217746A0 (en) | 2012-03-29 |
| CN102549013A (zh) | 2012-07-04 |
| KR101836130B1 (ko) | 2018-03-08 |
| US20120201829A1 (en) | 2012-08-09 |
| CA2769394C (en) | 2019-06-25 |
| EP2284193A1 (en) | 2011-02-16 |
| EP2464665B1 (en) | 2014-12-03 |
| EP2860191A1 (en) | 2015-04-15 |
| EP2464665A1 (en) | 2012-06-20 |
| IL217746A (en) | 2016-05-31 |
| KR20120047270A (ko) | 2012-05-11 |
| EP2860191B1 (en) | 2017-10-11 |
| US9249215B2 (en) | 2016-02-02 |
| CA2769394A1 (en) | 2011-02-17 |
| ES2651762T3 (es) | 2018-01-29 |
| RU2529946C9 (ru) | 2015-03-27 |
| CN102549013B (zh) | 2015-05-06 |
| RU2529946C2 (ru) | 2014-10-10 |
| JP6064241B2 (ja) | 2017-01-25 |
| ES2529175T3 (es) | 2015-02-17 |
| WO2011018208A1 (en) | 2011-02-17 |
| JP2013501506A (ja) | 2013-01-17 |
| RU2012105045A (ru) | 2013-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2012DN00797A (enExample) | ||
| PH12017500864A1 (en) | Anti-notch1 antibodies | |
| MY178926A (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
| IL214884A (en) | Two-specific, three-valent antibody, pharmaceutical preparations containing it and nucleic acids encoding it | |
| SG178886A1 (en) | Humanized anti-cdcp1 antibodies | |
| WO2010115552A8 (en) | Bispecific anti-erbb-3/anti-c-met antibodies | |
| MY162825A (en) | Antibodies for epidermal growth factor receptor 3 (her3) | |
| TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
| MX2010005888A (es) | Anticuerpos bivalentes biespecificos. | |
| MX2010005682A (es) | Anticuerpos bivalentes, biespecificos. | |
| MX2010006396A (es) | Anticuerpos bivalentes, biespecificos. | |
| UA100874C2 (en) | Bivalent bispecific antibodies | |
| MX336682B (es) | Anticuerpos contra csf-1r humanos y usos de los mismos. | |
| IL212633A (en) | A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs | |
| PH12014502406A1 (en) | Anti-il-23p19 antibodies | |
| UA106070C2 (uk) | Антитіло, що специфічно зв'язується з egfr і her3 | |
| PH12013500810B1 (en) | Anti-il-23 antibodies | |
| EA201291067A1 (ru) | Гуманизированные антигенсвязывающие белки к миостатину | |
| EA201001639A1 (ru) | Композиции и способы их получения и применения | |
| AU2011217848A8 (en) | Integrin aVB8 neutralizing antibody | |
| MX2013001267A (es) | ANTICUERPOS A IL-1ß E EIL-18 PARA TRATAMIENTO DE ENFERMEDAD. | |
| UA106529C2 (uk) | Гуманізоване антитіло до cxcr4 для лікування раку | |
| JO3437B1 (ar) | أجسام مضادة محسنة مضادة للفراكتالكين البشري واستخداماتها | |
| PH12015501360A1 (en) | Bmp-6 antibodies | |
| PH12013500432A1 (en) | Anti-vegfr-3 antibody compositions |